Published in Obstet Gynecol on October 01, 2004
Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif Tissue Int (2011) 1.50
The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol (2013) 1.44
Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int (2011) 1.13
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther (2009) 1.06
Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int (2010) 1.01
Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol (2008) 1.01
Screening, diagnosis and treatment of osteoporosis: a brief review. Clin Cases Miner Bone Metab (2014) 0.99
Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke (2008) 0.97
Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord (2010) 0.96
Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporos Int (2012) 0.91
Osteoporosis prevention and therapy: preserving and building strength through bone quality. Osteoporos Int (2006) 0.91
Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation. J Ocul Pharmacol Ther (2011) 0.86
Prostate cancer: Reducing fracture risk in men on androgen deprivation therapy. Nat Rev Urol (2010) 0.83
Osteoporosis and treatments in Japan: management for preventing subsequent fractures. J Bone Miner Metab (2013) 0.82
Cost-effectiveness of preventative therapies for postmenopausal women with osteopenia. BMC Womens Health (2007) 0.79
Hormone replacement therapy and the prevention of postmenopausal osteoporosis. Prz Menopauzalny (2014) 0.79
Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. Int J Womens Health (2010) 0.79
The effects of raloxifene treatment on oxidative status in brain tissues and learning process of ovariectomized rats. Iran J Reprod Med (2011) 0.77
Managing the risk of invasive breast cancer in women at risk for breast cancer and osteoporosis: the role of raloxifene. Clin Interv Aging (2008) 0.76
Time and dose-dependent effects of Labisia pumila on the bone strength of postmenopausal osteoporosis rat model. BMC Complement Altern Med (2015) 0.76
Cost-effectiveness of Pharmaceutical Interventions to Prevent Osteoporotic Fractures in Postmenopausal Women with Osteopenia. J Bone Metab (2016) 0.75
Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain. Clinicoecon Outcomes Res (2013) 0.75
Clinical update on the use of ospemifene in the treatment of severe symptomatic vulvar and vaginal atrophy. Int J Womens Health (2016) 0.75
Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia). Clin Interv Aging (2014) 0.75
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
The effects of tibolone in older postmenopausal women. N Engl J Med (2008) 3.96
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol (2005) 3.79
Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab (2007) 3.05
Suturing versus conservative management of lacerations of the hand: randomised controlled trial. BMJ (2002) 2.99
Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) Study: a randomized controlled trial. JAMA (2003) 2.62
Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol (2005) 2.47
Ethnic variation in bone density in premenopausal and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab (2002) 2.34
Hormone predictors of bone mineral density changes during the menopausal transition. J Clin Endocrinol Metab (2006) 2.01
Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer (2007) 2.01
Early discontinuation of treatment for osteoporosis. Am J Med (2003) 2.00
Cognitive function in postmenopausal women treated with raloxifene. N Engl J Med (2001) 1.87
Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the health, aging, and body composition study. J Bone Miner Res (2010) 1.86
Mammographic density and estrogen receptor status of breast cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.78
Comparison of methods to measure low serum estradiol levels in postmenopausal women. J Clin Endocrinol Metab (2006) 1.76
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol (2008) 1.74
Ethnic variation in bone turnover in pre- and early perimenopausal women: effects of anthropometric and lifestyle factors. J Clin Endocrinol Metab (2002) 1.69
Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry (2005) 1.62
Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab (2002) 1.59
Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause (2003) 1.56
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol (2008) 1.48
Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. Am J Obstet Gynecol (2003) 1.46
Predictors of difficulty when discontinuing postmenopausal hormone therapy. Obstet Gynecol (2003) 1.36
Higher risk of multiple falls among elderly women who lose visual acuity. Ophthalmology (2004) 1.27
A genome-wide association meta-analysis of circulating sex hormone-binding globulin reveals multiple Loci implicated in sex steroid hormone regulation. PLoS Genet (2012) 1.23
Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res (2004) 1.16
Tibolone for postmenopausal women: systematic review of randomized trials. J Clin Endocrinol Metab (2002) 1.08
FRAX facts. J Bone Miner Res (2009) 1.06
Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteoporosis. Arch Intern Med (2002) 1.05
Recommendations for optimal care of the fragility fracture patient to reduce the risk of future fracture. J Am Acad Orthop Surg (2004) 1.04
Clinical correlates of atypical femoral fracture. Bone (2012) 1.03
Homocysteine levels and risk of hip fracture in postmenopausal women. J Clin Endocrinol Metab (2009) 0.98
Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis. J Am Geriatr Soc (2004) 0.97
Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trial. Am J Cardiol (2002) 0.96
Gastric and duodenal safety of daily alendronate. Arch Intern Med (2002) 0.94
Prospective study of endogenous circulating estradiol and risk of stroke in older women. Arch Neurol (2010) 0.94
Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone (2006) 0.94
Methods for assessing fracture risk prediction models: experience with FRAX in a large integrated health care delivery system. J Clin Densitom (2011) 0.90
Fracture risk tool validation in an integrated healthcare delivery system. Am J Manag Care (2011) 0.90
The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause (2007) 0.89
Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women. J Bone Miner Res (2007) 0.87
Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) trial: 5-year gynecological outcomes. Menopause (2011) 0.86
Hospitalization and change in body composition and strength in a population-based cohort of older persons. J Am Geriatr Soc (2010) 0.86
Uterine and vaginal effects of unopposed ultralow-dose transdermal estradiol. Obstet Gynecol (2005) 0.84
Snoring, daytime sleepiness, and incident cardiovascular disease in the health, aging, and body composition study. Sleep (2013) 0.84
Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin (2004) 0.82
Selective removal of alkali metal cations from multiply-charged ions via gas-phase ion/ion reactions using weakly coordinating anions. J Am Soc Mass Spectrom (2015) 0.81
Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five-year results from the Postmenopausal Evaluation and Risk Reduction with Lasofoxifene (PEARL) trial. Circulation (2010) 0.80
Effect of isoflavones on lipids and bone turnover markers in menopausal women. Maturitas (2004) 0.80
Thyroid hormone use and the risk of hip fracture in women > or = 65 years: a case-control study. J Womens Health (Larchmt) (2003) 0.79
Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. Obstet Gynecol (2003) 0.79
Duloxetine in the treatment of women with stress urinary incontinence: results from DESIRE (Duloxetine Efficacy and Safety for Incontinence in Racial and Ethnic populations). Curr Med Res Opin (2006) 0.77
The strongest Brønsted acid: protonation of alkanes by H(CHB(11)F(11)) at room temperature. Angew Chem Int Ed Engl (2013) 0.77
The dopamine receptor D2 genotype is associated with hyperprolactinemia. Fertil Steril (2005) 0.76
A randomized controlled trial of a Chinese herbal remedy to increase energy, memory, sexual function, and quality of life in elderly adults in Beijing, China. Am J Med (2003) 0.76
Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol (2005) 0.75
Questioning the accuracy of a recent review of osteoporosis medications. Ann Intern Med (2009) 0.75
High-dose corticosteroid exposure and osteoporosis intervention in adults. Ann Allergy Asthma Immunol (2006) 0.75
Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms. Obstet Gynecol (2004) 0.75
Fragile fracture care management program. Perm J (2005) 0.75
For osteoporosis, are two antiresorptive drugs better than one? J Clin Endocrinol Metab (2002) 0.75
Rationale for a non-inferiority clinical trial design focused on subpopulations. Curr Med Res Opin (2004) 0.75
The Classic: Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. 1982. Clin Orthop Relat Res (2006) 0.75
Effect of raloxifene on the incidence of elevated low density lipoprotein (LDL) and achievement of LDL target goals in postmenopausal women. Curr Med Res Opin (2004) 0.75
Application of new method for evaluating performance of fracture risk tool. Am J Manag Care (2012) 0.75
Effects of oral raloxifene on serum estradiol levels and other markers of estrogenicity. Fertil Steril (2002) 0.75
Use of raloxifene among women with a history of breast cancer. Breast Cancer Res Treat (2006) 0.75